Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Sending More Drug GMP Warning Letters to Foreign Sites

This article was originally published in The Gold Sheet

Executive Summary

FDA warning letters are up at foreign sites and down at domestic sites as agency ramps up presence abroad. Inadequate OOS investigations and faulty testing of drug components were top violations; contamination was a common issue; firms cited included Novartis, Mylan, Smithkline Beecham, Lonza and Noven.

You may also be interested in...

After Issuing 40 Drug GMP Warning Letters in FY 2012, FDA Aims to Improve Drug Quality This Year

FDA Commissioner Margaret Hamburg said that improving drug product quality will be one of the agency’s highest priorities this year and advised industry to do the same as the agency spearheads a number of new initiatives in this area. Yet is FDA taking a similarly aggressive approach to enforcement, given that the number of drug GMP warning letter declined 23%?

Eisai Manufacturing Changes Again, With Biogen Idec In The Mix

Eisai and Biogen Idec formed a manufacturing alliance for oral solids and parenteral capabilities, as Eisai continues to tinker with its global manufacturing model. Eisai also takes a new approach to academic partnerships with University College London for neurological targets.

Contamination is Major Problem Seen in GMP Warning Letters

FDA’s aggressive enforcement against pharmaceutical manufacturers for GMP violations continued in the first half of the year through its use of warning letters. Inadequate contamination controls was a common deficiency found in eight of the 18 drug GMP warning letters, failure to investigate out-of-specification results continues to be the most frequent GMP deficiency in warning letters, and cites of stability problems are increasing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts